Back to discover
Drug

Moxifloxacin

Regulatory activity · MHRA
Emerging researchLate-stage development
Also known as Avelox, Moxeza, Moxifloxacin (Eqv-Moxeza), Moxifloxacin (Eqv-Vigamox)+6 more

Avelox, Moxeza, Moxifloxacin (Eqv-Moxeza), Moxifloxacin (Eqv-Vigamox), Moxifloxacin Ophthalmic, Vigamox, Moxifloxacine, Moxifloxacino, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid, Moxifloxacin Hydrochloride.

RxNorm139462ChEMBLCHEMBL32UNIIU188XYD42P
2
Research papers
13
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Insights into the toxic effects of moxifloxacin in Allium cepa through multiparametric experimental and in silico analyses

Industry2026-07-13Nature — Environmental Sciences

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Clinical trial2026-07-07Results expected Q4 2026 · ClinicalTrials.gov

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Phase 2C Trial of Stratified Patient-Centered Treatment Regimens for Active TB

Clinical trial2026-06-15Results expected Q2 2029 · ClinicalTrials.gov

A Phase 1, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-controlled, 4-period Crossover Study to Evaluate the Effect of a Single Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

Clinical trial2026-06-08Completed · ClinicalTrials.gov

A Phase I, Single-center, Randomized, Double-blind, Placebo- and Positive-controlled, Four-period, Crossover Clinical Study to Evaluate the Effect of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

Clinical trial2026-05-19Results expected Q3 2026 · ClinicalTrials.gov

Thorough QT/QTc Study of Staccato® Loxapine for Inhalation in Healthy Volunteers

Clinical trial2026-04-22Results posted · ClinicalTrials.gov

A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants

Clinical trial2026-04-09Completed · ClinicalTrials.gov

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

Clinical trial2026-01-20Results expected Q3 2031 · ClinicalTrials.gov

Drug Safety Update: Moxifloxacin: increased risk of life-threatening liver reactions and other serious risks

Regulatory2014-12-11MHRA

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Research2012-07-23Lancet (London, England)

Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.

Research2011-12-12International journal of antimicrobial agents

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Moxifloxacin
Aliases & brands
AveloxMoxezaMoxifloxacin (Eqv-Moxeza)Moxifloxacin (Eqv-Vigamox)Moxifloxacin OphthalmicVigamoxMoxifloxacineMoxifloxacino1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acidMoxifloxacin Hydrochloride
RxNorm CUI
139462
ChEMBL ID
CHEMBL32
UNII
U188XYD42P
Regulatory jurisdictions
mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
1
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2014-12-11Safety communicationSafety
Drug Safety Update: Moxifloxacin: increased risk of life-threatening liver reactions and other serious risks
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

195 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
195
registered trials across all phases
LATEST COMPLETION 2026
13
Active studies
11
Recruiting
52
Late-stage (III+)
166
Completed
16
Discontinued
PHASE DISTRIBUTIONn = 195
Early Phase 11Phase 1125Phase 1 / 22Phase 215Phase 2 / 34Phase 320Phase 419Phase N / A9

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

RecruitingPH IVFundacion Clinic per a la Recerca Biomédican=3602027

A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

CompletedPH IVDaiichi Sankyon=1402024

Antibiotic Resistance In Eye Surgeries (ARIES)

CompletedPH IVUniversity of California, San Franciscon=1082023

A Randomized, Double-Blind, 3-arm, Parallel Group, Placebo- and Positive-controlled Study to Investigate the Effects of Setmelanotide on QTc Interval in Healthy Subjects

CompletedPH IVRhythm Pharmaceuticals, Inc.n=772022

Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response

Unknown statusPH IVDavid Garcia Cincan=4242021

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 1, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-controlled, 4-period Crossover Study to Evaluate the Effect of a Single Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

CompletedPH ISanofin=482026

A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants

CompletedPH IMerck Sharp & Dohme LLCn=622026

A Double-Blind, Placebo-Controlled and Active-controlled Trial to Evaluate the Effect of a Supratherapeutic Dose of MK-8527 on the QTc Interval in Healthy Adult Participants

CompletedPH IMerck Sharp & Dohme LLCn=422025

A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group With Nested Crossover Design Trial With Moxifloxacin as Positive Control to Evaluate the Effects of Multiple Subcutaneous Doses of BI 456906 in a Titration Scheme on Cardiac Safety Parameters in (Otherwise) Healthy Male and Female Subjects With Overweight/Obesity

CompletedPH IBoehringer Ingelheimn=1102025

A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positive-controlled, Placebo-controlled, Parallel, Nested-crossover (Moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

CompletedPH IBristol-Myers Squibbn=742025

A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects

CompletedPH IAmgenn=322024

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes1
Stem Cell Transplantation1
Journals, researchers & institutions
Top journals
  • International journal of antimicrobial agents1
  • Lancet (London, England)1
Leading researchers
  • Arenz D1
  • Becker P1
  • Böll B1
  • Bredenfeld H1
  • Chemnitz J1
  • Cornely OA1
  • Cremer B1
  • Dawson R1
Leading institutions
free-text, unnormalised
  • Stellenbosch University1
  • University Hospital of Cologne1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.